

# IMPORTANT BC PHARMACARE PROGRAM INFORMATION DEXCOM G6 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM

The Dexcom G6 Continuous Glucose Monitoring (CGM) System is now covered through BC PharmaCare under Fair PharmaCare, Plan C or Plan W.

## How do patients qualify?

Residents of British Columbia, 2 years of age and older who live with diabetes mellitus (DM) and meet the following criteria:

1. Requires multiple daily injections of insulin<sup>1</sup> or insulin pump therapy as part of intensive insulin therapy, **AND**
2. The patient/family/caregiver agrees to comprehensive and age-appropriate diabetes education by an interdisciplinary diabetes healthcare team and commits to regular follow-up, **AND**
3. The patient has one of the following:
  - Hypoglycemia unawareness<sup>2</sup>, **OR**
  - Frequent and unpredictable hypoglycemic episodes<sup>3</sup>, **OR**
  - Unpredictable swings in blood glucose<sup>4</sup>, **OR**
  - At least one functional restriction that inhibits the use of blood glucose test strips (BGTS) (e.g., dexterity, mobility, dermatological problems), **OR**
  - An occupation where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers).

For a complete description of coverage criteria, please visit: <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/special-authority/special-authority-request-forms-drugs-medical-devices-and-supplies>

## How do patients get coverage?

Patients should first contact their primary care provider or endocrinologist to initiate the BC PharmaCare Special Authority approval process and receive a written prescription. If their approval is successful, their future Dexcom purchases will need to be made at their local pharmacy.

## What are the next steps for the patient?

Once the Special Authority application has been submitted, approval may take up to 3-4 weeks. Patients should confirm that the request has been approved before bringing their prescription to their local pharmacy. Patients may call their prescriber or pharmacist to confirm, or call PharmaCare at 1-800-663-7100 (toll-free) or 604-683-7151 (from the Lower Mainland).

When presenting their prescription at the pharmacy, the pharmacist will submit their coverage claim to BC PharmaCare and, when needed, coordinate coverage between BC Pharmacare and private insurance.

Please be aware that BC PharmaCare will not retroactively reimburse patients for benefits purchased before approval of a Special Authority request.

## How long will patients be covered for?

Once approved, the patient's initial request is valid for **one year**. After that time, coverage may be renewed for five years if the patient continues to require multiple daily injections of insulin<sup>1</sup> or insulin pump therapy as part of intensive insulin therapy and will benefit from continued use of a continuous glucose monitor.

## Who do I contact if I have questions?

**Healthcare professionals** can find helpful information, resources and videos online at [ca.provider.dexcom.com](http://ca.provider.dexcom.com), or may contact us by toll-free phone at 1-844-536-8388 or by email at [ca.hcpsales@dexcom.com](mailto:ca.hcpsales@dexcom.com).

**Patients** can find helpful information, resources and videos online at [Dexcom.com](http://Dexcom.com), or may contact us by toll-free phone at 1-844-832-1810 or by email at [ca.sales@dexcom.com](mailto:ca.sales@dexcom.com).

<sup>1</sup> Multiple daily injections of insulin is defined as 1 (or more) injection(s) of basal insulin and three (or more) injections of bolus insulin, with a minimum of at least of 4 total insulin injections per day.

<sup>2</sup> Hypoglycemia unawareness is defined as the inability of a patient to recognize or communicate early symptoms of hypoglycemia resulting in the inability to take corrective action to prevent severe hypoglycemic episodes.

<sup>3</sup> Frequent hypoglycemic episodes are defined as greater than 3 episodes per week. Unpredictable hypoglycemic episodes are defined as those that are not associated with predictable causes (e.g., physical activity, reduced food intake, acute illness, medication dosing errors).

<sup>4</sup> Unpredictable swings in blood glucose is defined as variability in blood glucose levels of less than 4 mmol/L and/or greater than 10 mmol/L throughout the day that are not associated with a predictable cause (e.g., physical activity, food intake, acute illness, medication dosing errors).

© 2021 Dexcom Canada, Co. All rights reserved. LBL021309 Rev001

Dexcom, Dexcom G6, Dexcom Share, Dexcom Follow and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.



# THE POWER TO CHANGE HOW PATIENTS LIVE WITH DIABETES

## Dexcom G6



Dexcom G6 measures glucose levels up to every five minutes using a sensor inserted just underneath the skin, and wirelessly transmits glucose readings to a receiver or compatible smart device.†



### Zero fingersticks\* or scanning required

No fingersticks\* needed for treatment decisions or insulin dosing



### Custom alerts and alarm

Customizable high and low glucose alerts, and an Urgent Low Soon alert that can proactively warn users if they will be  $\leq 3.1$  mmol/L within 20 minutes.



### Remote data sharing†

Capability to share glucose data with up to five loved ones



### 10-day sensor wear

New, extended 10-day sensor wear



### Dexcom CGM Lowers A1C<sup>1,5</sup>

Proven to reduce A1C and decrease risk of hypoglycemia for people using insulin<sup>1,3</sup>



### Reduces hypoglycemic events<sup>2,3</sup>

Demonstrated to reduce the number of hypoglycemic events in people with diabetes



### Increases time spent in range<sup>1,3</sup>

Dexcom CGM users spend more time in range than those using fingersticks



### Pediatrics

The only CGM approved for ages 2 years and up

For more info on Dexcom G6, visit us online:

## CA.PROVIDER.DEXCOM.COM

\* If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

† Internet connectivity required for data sharing. Following requires the use of the Follow App.

‡ For a list of compatible devices, visit [www.dexcom.com/compatibility](http://www.dexcom.com/compatibility).

1 Beck R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Injections for Insulin Delivery: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.

2 Heinemann L, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. The Lancet. 2018;391(10128): 1367-1377.

3 Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3).